Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome response of mouse mammary gland from age 12 to 30 months of age in Esr1 and CYP19A1 genetically engineered mouse models of breast cancer risk in the presence and absence of transgene induction

ABSTRACT: Transcriptome response of mouse mammary gland from age 12 to 30 months of age in Esr1 and CYP19A1 genetically engineered mouse models of breast cancer risk in the presence and absence of transgene induction

PROVIDER: PRJNA832964 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18961413.fastq.gz	Fastqsanger.gz
	SRR18961414.fastq.gz	Fastqsanger.gz
	SRR18961415.fastq.gz	Fastqsanger.gz
	SRR18961416.fastq.gz	Fastqsanger.gz
	SRR18961417.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Transcriptome response of mouse mammary gland from age 12 to 30 months of age in Esr1 and CYP19A1 genetically engineered mouse models of breast cancer risk in the presence and absence of transgene induction

Project description:Breast cancer is an age-related cancer in women with two peaks, one at 50 and one at 70 years of age. Here we used two conditional genetically engineered mouse models of breast cancer risk to study mammary gland transcriptional changes that occur as female mice age from 12 to 30 months of age, paralleling aging from 58 to 85 years of age in women. The two models express either mammary epithelial cell-targeted Estrogen Receptor (ER) alpha (Esr1) or Aromatase (CYP19A1A) over-expression beginning at age 12 or 18 months of age. Both of these risk factors increase estrogen pathway signaling, either directly though the receptor or by increasing local estrogen production. The goals of the study are to determine how quickly significant transcriptional changes occur in the mammary gland following transgene induction, to determine how the transcriptome becomes modified as the mice age past reproductive senescence through old and very old life stages, and to identify similarities and differences in the transcriptomes between the two risk conditions at different ages and conditions. The first specific objective of this transcriptome-based study is to identify significantly differentially expressed genes within each model between different ages and times of transgene induction. This includes transcriptional changes induced by 1 week, 6, 12 and 18 months of transgene expression with transgene expression initiated at age 12 months as well as transcriptional changes induced by 1 week and 6 months of transgene expression initiated at age 18 months. The second specific objective is to compare the two models at different ages (12, 18, 24 and 30 months of age) and different transgene induction times (6, 12 and 18 months) to identify differentially expressed genes between the models. Comparative control mice from each model include age 18- and 24-month-old mice without transgene induction.

2022-08-22 | GSE201767 | GEO

Transcriptome response to anti-hormonals in Esr1 and CYP19A1 genetically engineered mouse models of breast cancer risk during reproductive senescence

Project description:Reproductive senescence is an age-associated process in which reproductive capacity is reduced. In female mice this is associated with loss of oocytes and a corresponding reduction in ovarian estrogen production. Normal mammary gland development and function is linked to estrogen stimulation. In this study we utilize two genetically engineered mouse models of breast cancer risk, one with mammary-targeted conditional expression of Esr1, the RNA that encodes Estrogen Receptor alpha, and one with mammary-targeted conditional expression of CYP19A1, the RNA that encodes Aromatase, the enzyme that is responsible for estrogen synthesis from androgens to determine how reproductive senescence impacts the transcriptional response to commonly used anti-hormonals employed for breast cancer prevention, tamoxifen and letrozole. The goals of the study are, first, to test the extent to which each of these anti-hormonals alter the mammary gland transcriptome in mice undergoing reproductive senescence and, second, determine if the response is the same or different in the presence of Esr1 as compared to CYP19A1 transgene expression targeted to mammary epithelial cells. The objectives are to identify specific genes that are significantly differentially expressed genes within each model between treatment conditions control, tamoxifen and letrozole as well as between models under each of these conditions. Transcriptome comparisons between 18- and 20-month-old mice are used to identify differences between the two models as ovarian function diminishes during reproductive senescence. Transcriptome comparisons between cohorts of 20-month-old mice that received no anti-hormonal or a two-month-exposure to tamoxifen or letrozole beginning at age 18 months are used to identify similarities and differences between the two anti-hormonal treatments as well as similarities and differences between models.

2022-08-07 | GSE201326 | GEO

Mouse Striatum 18 months of age

Project description:Mouse Striatum 18 months of age

| PRJNA938920 | ENA

Estrogen receptor alpha (ESR1)-dependent regulation of the mouse oviduct

Project description:Estrogen receptor-α (ESR1) is an important transcriptional regulator in the mammalian oviduct, however ESR1-dependent regulation of this organ is not well defined, especially at the genomic level. The objective of this study was therefore to investigate estradiol- and ESR1-dependent regulation of the transcriptome of the oviduct using transgenic mice, both with (ESR1KO) and without (wild-type, WT) a global deletion of this transcription factor using the Affymetrix Genechip Mouse Genome 430-2.0 arrays.

2015-11-30 | GSE72614 | GEO

esr1-drn-Transcriptomic study of the transcription factor ESR1/DRN.

Project description:adt06-01_esr1-drn_dexamethasone - esr1-drn - Identification of the target genes of the ESR1/DRN TF using dexamethasone induction - Identification of the target genes of the ESR1/DRN TF using dexamethasone induction Keywords: normal vs transgenic comparison 5 dye-swap - CATMA arrays

2008-09-25 | E-GEOD-12919 | biostudies-arrayexpress

Mouse Liver: Tumors vs Two Week Transgene Expression vs Normal

Project description:Transcriptional Profiling of mouse liver tissues comparing normal tissues, tissues with two weeks expression of transgene, and tumors arising from transgene expression after hepatocy transplantation using the comparative hepatocyte growth assay Experimental groups: Control (hPAP marker gene); Normal Liver Expressing Transgene for Two Weeks; Liver Tumors Expressing Transgene

2014-08-15 | GSE59194 | GEO

Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase over-expressing mice defines an immune-associated gene signature linked to tamoxifen resistance

Project description:To investigate response or resistance to endocrine therapy, mice with targeted over-expression of Esr1 or CYP19A1 to mammary epithelial cells were employed, representing two direct pathophysiological interventions in estrogen pathway signaling. Both Esr1 and CYP19A1 over-expressing mice responded to letrozole with reduced HAN prevalence and decreased mammary epithelial cell proliferation. CYP19A1 over-expressing mice were tamoxifen-sensitive but Esr1 over-expressing mice were tamoxifen-resistant. Increased ER expression occurred with tamoxifen resistance but no consistent changes in progesterone receptor, pSTAT3, pSTAT5, cyclin D1 or cyclin E levels in association with response or resistance was found. RNA-seq was employed to seek a transcriptome predictive of tamoxifen resistance using these models and a second tamoxifen-resistant model, BRCA1 deficient/Trp53 haploinsufficient mice. Sixty-eight genes associated with immune system processing were upregulated in tamoxifen-resistant Esr1 and Brca1 deficient mice whereas genes related to aromatic compound metabolic process were upregulated in tamoxifen-sensitive CYP19A1 mice. Interferon Regulatory Factor 7 was identified as a key transcription factor regulating these 68 immune processing genes. Two loci encoding novel transcripts with high homology to human IGLL1 were uniquely upregulated in the tamoxifen-resistant models. Letrozole proved to be a successful alternative to tamoxifen. Further study of transcriptional changes associated with tamoxifen resistance including immune-related genes could expand our mechanistic understanding and lead to biomarkers predictive of escape or response to endocrine therapies. Single- and paired-end mRNA-seq with WT, Esr1 over-expressing (CERM, tetracycline-operator(tet-op)-Esr1MMTV-rtTA), CYP19A1 over-expressing (AROM, tet-op-CYP19A1MMTV-rtTA) and Brca1 KO (BRCA, Brca1fl11/fl11/MMTV-Cre/p53+/- ) mice

2014-12-04 | E-GEOD-63857 | biostudies-arrayexpress

esr1-drn-Transcriptomic study of the transcription factor ESR1/DRN.

2008-09-26 | GSE12919 | GEO

FOXL2 and ESR1 binding sites in primary cells from mouse ovarian follicles

Project description:It has previously been shown that FOXL2 and ESR1 cooperate to repress the testis-determining gene Sox9 in murine granulosa cells, and suggested that FOXL2/ESR1 cooperation may be central to granulosa cell differentiation (Uhlenhaut et al., 2009). However, no study has so far compared the DNA-binding of FOXL2 and ESR1 at the genomic level or analyzed the impact of FOXL2 on ESR1 binding to its regulatory elements. Here, we have analyzed and compared the genomic locations recognized by ESR1 and FOXL2 in E2-treated primary murine granulosa cells. Input DNA, FOXL2 and ESR1 ChIP

2015-07-01 | E-GEOD-62545 | biostudies-arrayexpress

FOXL2 and ESR1 binding sites in primary cells from mouse ovarian follicles

2015-07-01 | GSE62545 | GEO